Connect with us

News

Cohealo to Mitigate COVID-19 Ventilator Shortages by Sharing Between Hospitals

gbafNews28

Cohealo, a platform for health systems to track and share medical equipment, today announced that the company will begin onboarding customers to their national ventilator sharing network. The solution will enable health systems to monitor capacity and dynamically mobilize ventilators to the hospitals that need them most.

Ventilators are in critical supply from the COVID-19 pandemic. Nationally, there are estimated to be as few as 100,000 ventilators with only an additional 12,700 in the strategic stockpile. The CDC has predicted that 160 million to 214 million people in the United States could be infected during the pandemic, with models projecting a need for more than 250,000 ventilators to combat the outbreak.

The time for sharing is now, said Todd Rothenhaus, M.D., Cohealos chief executive officer. To date, the pandemic has not hit every part of the nation equally. Optimizing ventilators between geographically disparate locations has the potential to stretch existing ventilator capacity to reduce morbidity and save lives.

Cohealo has conducted more than 5,000 shares of 127 different equipment types, with expertise in mobilizing even the most delicate of assets, including microscopes, lasers, and surgical robots. The company retains 99.9% move reliability with specialized workflows that diminish the potential for breakage or delays.

With almost a decade of experience tracking and sharing medical equipment for some of the largest health systems in the country, our team is poised to solve this challenge, said Brett Reed, Cohealos chief operating officer. Hospitals have an urgent need for ventilators, and we have logistics in place to get these assets to patients quickly.”

Using the Cohealo platform, hospitals can upload inventory, track usage, and develop an operating picture of available capacity across all participating facilities. When there are spikes in demand, the system selects the best candidates for sharing and quantities to be moved.

End-to-end logistics is supported directly in the platform, including waybill creation, mobilization procedures, and chain of custody. This process ensures equipment is transported safely and that ventilators are returned to point of origin. Additionally, health systems have access to a digital equipment catalogue that contains profiles of each ventilator type, ensuring all the relevant make/model details and OEM manuals are available for respiratory therapists and biomedical teams.

Together, we have the ability to maximize the use of ventilators during this crisis. We have tremendous capacity as a healthcare system to get doctors the resources they need, said Rothenhaus.

To join Cohealos national ventilator sharing network, visit https://cohealo.com/

About Cohealo

Based in Boston, Cohealo is recognized as the first company to bring the sharing economy to healthcare. Using Cohealo, health systems can track equipment utilization, identify candidates for sharing, and save money by right-sizing their inventory during the capital planning process. Cohealo optimizes equipment for health systems across the United States and for the National Healthcare Service in the United Kingdom in partnership with DHL. Cohealo has been named to Fast Companys Most Innovative Companies List and CNBCs Disruptor 50.

Danielle Goldschneider

Senior Product Marketing Manager

857-383-6047

[email protected]

News

New Development Fuels Net Lease Auto Sector

gbafNews28

WILMETTE, Ill., Feb. 24, 2021 /PRNewswire-PRWeb/ — The Boulder Group announced the release of its Net Lease Auto Report today. In the fourth quarter national asking cap rates in the single tenant auto sector decreased to 5.89%, according to the 2020 Net Lease Auto Report. This represented a 48 basis point decrease when compared to the prior year. The auto sector, for the purpose of this report, consists of various auto related tenants in the parts, service and collision sectors.

“The primary reason contributing to the substantial decrease in cap rates was an increase in supply of new construction properties with longer term leases,” says Randy Blankstein, President, The Boulder Group.

According to the report, the new development supply was primarily concentrated in the service and collision sectors as these tenants continue to expand their footprints nationally. In recent years, new store development for the auto parts sector has lagged behind historical standards which has limited the supply of long term leased properties in the auto parts sector. In the fourth quarter of 2020, the median term remaining in the auto parts sector was less than eight years.

“Accordingly, many net lease investors shifted their focus to the service and collision sectors which have been underweighted in investors' portfolios historically,” adds Jimmy Goodman, Partner, The Boulder Group.

The service and collision sectors held a median term remaining of approximately 12 years in the fourth quarter of 2020. Accordingly, the auto sector to commanded an 11 basis point premium over the overall net lease retail sector in the fourth quarter of 2020. In the fourth quarter of 2019, the auto sector was inversely priced at a 30 basis point discount.

“Investors' appetite for net lease auto properties can be directly attributed to strong corporate tenancy, typical rent bumps and varied degrees of e-commerce resistance,” John Feeney, Senior Vice President, The Boulder Group adds. “Additionally, the lower price points associated with this sector creates a larger buyer pool.”

In the fourth quarter of 2020, the median asking price for the auto sector was approximately $2 million

Transaction volume in the auto sector should remain similar to 2020 as investors continue to seek properties with strong tenants in the price range this sector provides. “There will continue to increased competition for new construction assets as 1031 and private investors favor these properties,” according to Blankstein. “Auto properties with shorter lease terms located in areas with strong real estate fundamentals also remain in strong demand among buyers seeking higher yields.”

To view the full report: https://bouldergroup.com/media/pdf/Net-Lease-Auto-Report.pdf

About The Boulder Group

The Boulder Group is a boutique, Chicago-based investment real estate services firm specializing in transaction and advisory services for single tenant net lease properties. Founded in 1997, the firm has closed over $6 billion of net lease property transactions. The firm provides a full range of brokerage, research, advisory, and financing services nationwide. The level of annual, single-tenant transaction volume consistently ranks the firm in the top 10 companies nationally, according to industry benchmarks determined by CoStar and Real Capital Analytics.

Media Contact

Randy Blankstein, The Boulder Group, +1 8475620003, [email protected]

Twitter

 

SOURCE The Boulder Group

Continue Reading

News

The Valens Company Reports Financial Results for the Fourth Quarter and Fiscal Year Ended November 30, 2020

gbafNews28

Strategic transformation from industry-leading extractor to largest third-party cannabis product manufacturer in Canada driving 292% Q4 2020 provincial sales growth

Increased Cannabis 2.0 market share to ~4.9% in Alberta, British Columbia and Ontario based on Headset data, not including B2B LP manufacturing

Valens reiterates Q1 2021 revenue guidance of $19 to $23 million

KELOWNA, BC, Feb. 24, 2021 /PRNewswire/ – The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the “Company,” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, is pleased to report its fourth quarter and fiscal year financial results for the period ended November 30, 2020.

“In fiscal year 2020, we transformed Valens from a leading extraction company into the industry's most trusted third-party manufacturer of cannabis consumer packaged goods. Over the course of the year, we strategically employed our human and capital resources to strengthen our platform and build the infrastructure required to offer what we believe are the most innovative and cost competitive product manufacturing capabilities in the market today,” said Tyler Robson, Chief Executive Officer, Co-Founder and Chair of The Valens Company. “Moving into 2021 with a transformed business model, a growing international presence, and over 77,000 square feet of manufacturing space, Valens is focused on three key initiatives – growing unit volumes per SKU, increasing Cannabis 2.0 and 3.0 product market share, and driving revenues in new consumer verticals. We expect to do this by expanding our provincial distribution capabilities, entering new international markets including the US, and broadening our custom manufacturing and white label partnership network.”

Key Highlights

  • Net revenue increased 44% to $83.8 million in fiscal 2020 compared to $58.1 million in fiscal 2019
  • Product sales increased 237% to $54.7 million in fiscal year 2020 over 2019
  • Product sales as a percentage of net revenue increased from 83% in Q3 2020 to 90% in Q4 2020
  • Provincial sales, included as part of product sales revenue, increased 292% from Q3 2020 to Q4 2020 
  • Q4 2020 represented Valens' first full quarter of provincial sales with a broader SKU offering spanning various Cannabis 2.0 categories such as concentrates, vapes, beverages and oils
  • Increased market share to ~4.9% of the Cannabis 2.0 market in Alberta, British Columbia, and Ontario in Q4 2020 based on Headset data and not including B2B LP manufacturing, and grew cannabis-infused beverage market share in Canada to approximately 5.2% in Q4 2020 for its product lineup with only one customer in this category to date
  • Manufactured 62 SKUs in Q4 2020, an increase of 11% over Q3 2020, including product formats in a number of categories such as tinctures, vapes, concentrates, and beverages
  • Cemented position as the largest third party vape manufacturer in Canada
  • Transitioned from shipping bulk distillate in Q1 2020 to shipping hundreds of thousands of finished product units per month in Q4 2020, resulting in revenue which is expected to be recurring in nature
  • Q4 and Fiscal Year 2020 Corporate and Operational Summary:

    • Leading the Canadian cannabis product manufacturing market, having worked alongside over 30 licensed producers, including securing over 10 white label and custom manufacturing agreements.
    • Launched new and innovative Cannabis 2.0 product formats, including cannabis-infused beverages and hydrocarbon-derived crumble in partnership with brand house partners.
    • Maintained strong capital position with a current cash balance of $48.7 million, including gross proceeds of $39.7 million from the bought deal financing that closed subsequent to quarter end.
    • Grew domestic manufacturing capacity with the completion of Valens 42,000 square foot K2 Facility. In the fourth quarter, Valens received an amendment to its existing Health Canada standard processing licence to allow operations to commence at the facility and has since commissioned the manufacturing of various product formats such as vapes, tinctures, beverages, and bath bombs. With the additional capacity at the K2 Facility coming online, in addition to the 30,000 square foot GTA Facility nearing completion, Valens is readying its platform to increase finished product output for continued execution in the Cannabis 2.0 and 3.0 markets.
    • Expanded internationally with entry into the Australian market through a distribution agreement with the country's largest medicinal cannabis distributor, Cannvalate Pty Ltd. (“Cannvalate”). In fiscal year 2020, Valens began to monetize the Cannvalate agreement with shipments of tinctures into the Australian market and expects to continue to introduce innovative products, such as topicals and water-soluble drops, in fiscal 2021. Subsequent to quarter end, in Q1 2021, the Company made its first successful shipment of product samples, including CBD isolate and THC and CBD distillate, to Denmark after being selected to support a research and development initiative for a pharmaceutical company.
    • Strengthened corporate governance with the addition of new independent members to Valens' Board of Directors (“Board”) with significant legal, financial, and business knowledge and experience. Additionally, the Company marked a milestone with its uplisting from the TSX Venture Exchange to the Toronto Stock Exchange (the “TSX”).
    • Enhanced R&D and innovation platform through Health Canada's approval of Valens' cannabis research licence. The licence provides Valens the competitive market advantage to conduct controlled sensory evaluation of its products, including vapes, beverages and edibles, furthering its ability to develop consumer-driven insights to drive continued manufacturing excellence. Additionally, in the fourth quarter, Valens added SōRSE Clear, a stable, clear emulsion with a minimal sensory profile, to the SōRSE by Valens offering for CBD isolate product formats. This comes after the expansion of Valens' exclusive SōRSE agreement at the beginning of fiscal year 2020, allowing the Company to bring the leading cannabis infusion technology beyond Canada to international markets such as Australia, Europe Mexico, and the UK.

    Q4 and Fiscal Year 2020 Financial Summary:

    • Net revenue increased 44% to $83.8 million in fiscal 2020 compared to $58.1 million in fiscal 2019.
    • In Q4 2020, net revenue was $16.0 million compared to $18.1 million in Q3 2020.

    Net Revenue Breakdown (in thousands of Canadian dollars)

    Fiscal year ended
    November 30, 2020

    $

    Fiscal year ended
    November 30, 2019

    $

    Product Sales

    54,674

    16,200

    Toll Processing and Co-Packing

    27,281

    41,595

    Analytical Testing

    1,684

    311

    Other Revenue

    139

    Total Net Revenue

    83,778

    58,106

    Product sales revenue, including both provincial sales and B2B sales of finished goods, distillate, isolate, and other ingredients:

      • Increased 237% to $54.7 million in fiscal 2020 over fiscal 2019, comprising 65% of total net revenue in fiscal 2020
      • In Q4 2020, product sales made up 90% of net revenue at $14.5 million, a 4% decrease from $15.1 million in Q3 2020, which can be attributed to an inventory repositioning that resulted in lower sale prices on bulk distillate
      • Product sales as a percentage of net revenue increased from 83% in Q3 2020 to 90% in Q4 2020
      • Provincial sales, included as part of product sales revenue, increased 292% from Q3 2020 to Q4 2020
    • Gross profit was $25.7 million, or 29.9% of revenue, in fiscal 2020, compared to $41.4 million, or 71.2% of revenue, in fiscal 2019. Gross margin percentage was impacted by both our transition to product development and manufacturing, as well as an impact from the previously announced inventory write-down. This realignment included a realized loss on the sale of bulk oil of $(3.2 million), loss on onerous contracts of $(1.8) million, and inventory valuation allowance of $(9.3) million. Adjusting for these items, gross profit would have been $40.0 million or 46.5% gross margin. 
      • Gross profit (loss) was $(6.0) million, in Q4 2020, compared to $7.3 million, in Q3 2020.  The negative gross profit was the result of previously announced inventory write-down in fiscal Q4 2020. Adjusting for these items gross profit for the quarter would have been $3.9 million or 24.2% gross margin. By rebuilding its inventory with targeted strains of dried cannabis, sourced at opportunistic lower price points, Valens believes it now has the opportunity to decrease its cost of goods sold and compete more effectively on price to drive market share growth.
    • Adjusted EBITDA(1) was $14.1 million or 16.4% of revenue in fiscal year 2020, compared to $27.5 million, or 47.3% of revenue, in fiscal year 2019.
      • In Q4 2020, Adjusted EBITDA was $(4.3) million, compared to $1.4 million in Q3 2020. Adjusted EBITDA was impacted by the Company's previously announced strategic inventory realignment and an increase in operating expenses as the Company continues to scale its operations and build out its manufacturing platform.

      Fiscal 2021 Strategic Initiatives

      • Enter the US market and other international markets, as broader legal and regulatory frameworks continue to evolve, and, with respect to cannabis products, subject to legalization at the federal level and dependent on the requirements of the TSX. Valens will look to enter strategic partnerships and acquisitions with leaders in their respective markets.
      • Utilize data-driven expertise gained as a category leader in vape manufacturing to expand its leadership in new verticals, such as edibles, concentrates, beverages and 3.0 products. The Company expects to achieve this with its accelerated entry into the edibles market with its recent acquisition of LYF Food Technologies Inc. (“LYF”), which is expected to close on or around March 1, 2021.
      • Expand domestic distribution network beyond Alberta, British Columbia, Ontario, and Saskatchewan to all provincial markets, including near-term entry to Manitoba and Quebec, to drive greater market share and distribution capabilities.
      • Gain Canadian recreational market share with brand & consumer package good partners with the launch of new products for the Cannabis 2.0 and 3.0 markets, including edible and topical products targeted for the health and wellness market.
      • Achieve EU GMP Certification and broaden already fast-growing international shipments, including increased sell-through in existing international markets such as Australia, and globally with an emphasis on Europe.
      • Increase custom manufacturing and white label agreements and continue to innovate in partnership with its existing customers. Subsequent to Q4 2020, The Valens Company launched THC and CBD water-soluble drops under a custom manufacturing agreement with Verse Cannabis (“Verse”), and nūance's CBD 100 isolate formulation created for Medical Cannabis by Shoppers. Additionally, the Company secured an amendment to its existing Health Canada standard processing licence permitting the sale of dried cannabis products.

      Valens reiterates its previously announced guidance for Q1 2021 with revenue projected to be between $19 million to $23 million, driven by the Company's newly launched and operational K2 Facility which is expected to give Valens the ability to increase product capabilities and unit volumes.

      Jeff Fallows, President of The Valens Company, said, “Over the course of 2020, Valens has created a platform that is not only highly adaptable to changing market conditions, but also easily transportable into new markets. Moving into fiscal year 2021, we have already executed on step one of our strategic plan for the year with the announcement of our agreement to acquire LYF and are focused on quickly integrating and realizing on the incredible opportunity we see in adding their edibles platform to our capabilities. With our recent bought deal financing, we are also well-positioned to aggressively pursue available and future growth opportunities, including potential acquisitions. We are now more excited than ever about the future of Valens and the potential for us to create shareholder value in 2021 and beyond.”

      The following table of financial highlights is presented in thousands of Canadian dollars, except per share, biomass extracted amounts and number of SKUs.

      Three-months
      ended November
      30, 2020;
      Q4 2020

      Three-months
      ended August 31,
      2020;
      Q3 2020

      Fiscal year
      ended November
      30, 2020

      Fiscal year
      ended November
      30, 2019

      Gross Revenue $

      17,932

      18,517

      86,059

      58,106

      Net Revenue $

      16,044

      18,128

      83,778

      58,106

      Gross Profit (loss) $

      ($5,993)

      7,313

      25,724

      41,351

      Gross Profit %

      N/A

      39.5%

      29.9%

      71.2%

      Adjusted EBITDA $ (1)

      (4,280)

      1,440

      14,139

      27,471

      Adjusted EBITDA % (1)

      N/A

      7.8%

      16.4%

      47.3%

      Net loss $

      (16,634)

      (3,064)

      (20,682)

      (6,536)

      Net loss %

      N/A

      N/A

      N/A

      N/A

      Basic / diluted loss per share $

      (0.13)

      (0.02)

      (0.16)

      (0.06)

      Cash and short-term investments $

      21,376

      30,257

      21,376

      58,701

      Biomass extracted (Kilograms) (2)

      10,311

      8,054

      68,386

      61,394

      Number of SKUs

      62

      56

      N/A

      N/A

      (1)

      Adjusted EBITDA is a non-GAAP measure used by management that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.  Management defines adjusted EBITDA as loss and comprehensive loss from operations, as reported, before interest, tax, depreciation and amortization, and adjusted for removing share-based payments, realized gains and losses from short term investments and liabilities and other one-time and non-cash items including impairment losses. Management believes adjusted EBITDA is a useful financial metric to assess its operating performance on an adjusted basis as described above. See reconciliation of “Adjusted EBITDA (non-GAAP measure)” in the Company's Management's Discussion and Analysis for the period ended November 30, 2020 for additional information.

      (2)

      Biomass extracted includes input from Licensed Producer partners for toll processing, in addition to the Company's own biomass inventory for 2.0 products.

      The management's discussion and analysis for the period and the accompanying financial statements and notes are available under the Company's profile on SEDAR at www.sedar.com.

      Q4 and Fiscal Year 2020 Conference Call Details

      The Company will host a conference call on Thursday, February 25, 2021 at 11:00 am Eastern Time / 8:00 am Pacific Time to discuss the financial results and business outlook.

      Participant Dial-In Numbers:

      Toll-Free:  1-877-407-0792
      Toll / International:  1-201-689-8263
      *Participants should request The Valens Company Earnings Call or provide confirmation code 13716273.

      The call will be available via webcast on the Valens investor page of the Company website at https://thevalenscompany.com/investors/ or at this link. Please visit the website at least 15 minutes prior to the call to register, download, and install any necessary audio software. A replay of the call will be available on the Valens investor page approximately two hours after the conference call has ended.

      Tyler Robson, Chief Executive Officer, Chris Buysen, Chief Financial Officer, Jeff Fallows, President, and Everett Knight, Executive Vice President of Corporate Development and Capital Markets, will be conducting a question-and-answer session following the prepared remarks.

      About The Valens Company
      The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services across five core technologies, in addition to best-in-class product development, formulation and manufacturing of cannabis consumer packaged goods. The Valens Company's high-quality products are exclusively formulated for the medical, therapeutic, health and wellness, and recreational consumer segments, and are offered across numerous product formats, including oils, vapes, concentrates, edibles and topicals, as well as pre-rolls, with a focus on next-generation product development and innovation. Its breakthrough patented emulsification technology, SōRSE™ by Valens, converts cannabis oil into water-soluble emulsions for seamless integration into a variety of product formats, allowing for near-perfect dosing, stability, and taste. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through its wholly owned subsidiary Valens Labs Ltd., the Company is setting the standard in cannabis testing and research and development with Canada's only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company and its subsidiaries at http://www.thevalenscompany.com.

      Notice regarding Forward Looking Statements

      All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management's expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management's current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “forecasts”, “future”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “should”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions (including the LYF Acquisition), economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.

      The risks and uncertainties that may affect forward-looking statements include, among others,  Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company's latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company's website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management's current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.

      Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/the-valens-company-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-november-30-2020-301235068.html

      SOURCE The Valens Company Inc.

      Continue Reading

      News

      AIFA Invites Demotech to Participate in March 2021 Annual Conference

      gbafNews28

      COLUMBUS, Ohio, Feb. 24, 2021 /PRNewswire/ — Demotech, Inc. has been invited to be part of the Rating Agency panel at the 2021 annual meeting of the Association of Insurance and Financial Analysts (AIFA).  Given corporate travel restrictions and other issues associated with COVID-19, the meeting will be virtual.  Information can be found at AIFA Conference 2021 – AIFA (aifa-insurance.com)

      The Rating Agency panel will be moderated by Paul Newsome, Managing Director, Piper Sandler & Co.  Barry J. Koestler II, CFA, Chief Ratings Officer, will represent Demotech.  According to Joe Petrelli, President and Co-founder, Demotech, Koestler is an ideal participant for the audience of AIFA.  “Barry has more than 25 years of insurance focused analytical experience.  In addition to coordinating the reviews and analyses of the more than 400 insurers that we formally follow, during his career Barry has reviewed thousands of business models and business plans including those prepared by InsurTechs.  Those attending an AIFA event deserve to hear the observations of a seasoned professional who shares the Chartered Financial Analyst designation. 

      Scheduled for March 1 and 2, 2021, registrations are still being accepted.

      The Association of Insurance and Financial Analysts (AIFA)
      The Association of Insurance and Financial Analysts is a non-profit organization coordinated by volunteers from the insurance investment community.  Their mission is to provide an annual conference forum to address the issues, challenges, and opportunities facing the P&C insurance, life insurance, reinsurance, and insurance brokerage industries.  Visit www.aifa-insurance.com

      Demotech, Inc.
      Demotech, Inc. is a financial analysis firm specializing in evaluating the financial stability of independent, regional, and specialty insurers.  Demotech's philosophy is to review and evaluate insurers based on their area of focus and execution of their business model rather than solely on financial size.  Demotech reviews and rates more than 400 insurers operating in the US, more than 225 of these insurers are uniquely rated by Demotech.  Visit www.demotech.com.

      Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aifa-invites-demotech-to-participate-in-march-2021-annual-conference-301235064.html

      SOURCE Demotech, Inc.

      Continue Reading
      Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

      Call for Entries

      Global Banking and Finance Review Awards Nominations 2021
      2021 Awards now open. Click Here to Nominate

      Latest Posts

      gbafNews28 gbafNews28
      News2 hours ago

      VivoPower International PLC Reports Financial Results For The Six Months Ended December 31, 2020 and Landmark Global Battery Partnership with Tottenham Hotspur

      Revenue, GP and EBITDA decline due to strict COVID-19 lockdowns in Australia Strategic pivot to enter commercial electric vehicle (EV)...

      gbafNews28 gbafNews28
      News2 hours ago

      Solar Capital Partners Rebrands to SLR Capital Partners

      NEW YORK, Feb. 24, 2021 /PRNewswire/ — Solar Capital Partners, LLC, a leading commercial finance platform with expertise across cash...

      gbafNews28 gbafNews28
      News2 hours ago

      Farmer Mac Appoints Eric T. McKissack to Board of Directors

      WASHINGTON, Feb. 24, 2021 /PRNewswire/ — The Federal Agricultural Mortgage Corporation (Farmer Mac; NYSE: AGM and AGM.A), the nation's secondary market...

      gbafNews28 gbafNews28
      News2 hours ago

      AIFA Invites Demotech to Participate in March 2021 Annual Conference

      COLUMBUS, Ohio, Feb. 24, 2021 /PRNewswire/ — Demotech, Inc. has been invited to be part of the Rating Agency panel...

      gbafNews28 gbafNews28
      News2 hours ago

      The Valens Company Reports Financial Results for the Fourth Quarter and Fiscal Year Ended November 30, 2020

      Strategic transformation from industry-leading extractor to largest third-party cannabis product manufacturer in Canada driving 292% Q4 2020 provincial sales growth...

      gbafNews28 gbafNews28
      News2 hours ago

      New Development Fuels Net Lease Auto Sector

      WILMETTE, Ill., Feb. 24, 2021 /PRNewswire-PRWeb/ — The Boulder Group announced the release of its Net Lease Auto Report today....

      gbafNews28 gbafNews28
      News2 hours ago

      USHG Acquisition Corp. Announces Pricing of $250 Million Initial Public Offering

      NEW YORK, Feb. 24, 2021 /PRNewswire/ — USHG Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering...

      gbafNews28 gbafNews28
      News2 hours ago

      Coleman Institute Withdrawal Management Now Covered by BCBS of MA

      WELLESLEY, Mass., Feb. 24, 2021 /PRNewswire-PRWeb/ — The Coleman Institute for Addiction Medicine, specialists in addiction treatment services for over...

      gbafNews28 gbafNews28
      News2 hours ago

      Launch of $2.65 billion Green Bond Offering

      LUXEMBOURG, Feb. 24, 2021 /PRNewswire/ — Ardagh Group (“Ardagh”) (NYSE:ARD) announces that Ardagh Metal Packaging S.A. (“AMP” or the “Company”)...

      gbafNews28 gbafNews28
      News2 hours ago

      Grupo Elektra Announces Revenues Of Ps.33,663 Million And EBITDA Of Ps.4,125 Million In 4Q20

      MEXICO CITY, Feb. 24, 2021 /PRNewswire/ — Grupo Elektra, S.A.B. de C.V. (BMV: ELEKTRA*; Latibex: XEKT), Latin America's leading specialty...